Advances in PH Journal
Advances in Pulmonary Hypertension Winter 2006 (Vol 5, No 4)
- Editor's Memo
Reflecting on Progress in PH and Appreciating the Contributions of Our Physicians
- Profiles in Pulmonary Hypertension: Victor F. Tapson, MD
Victor Tapson, MD: Clinical Trialist, Role Model, and Mentor to the Next Generation of PH Specialists
- Oral Therapies for PAH: State-of- the-Art and Investigational Approaches
Pulmonary arterial hypertension is often difficult to diagnose and challenging to treat. Untreated, it is characterized by a progressive increase in pulmonary vascular resistance leading to right ventricular dysfunction, impairment in activity tolerance, and death.
- Combination Therapy for PAH: Current Rationale, Future Concepts
The prostanoids have revolutionized treatment of pulmonary arterial hypertension. Intravenous, subcutaneous, and inhaled formulations are approved for use in the United States, while oral preparations are being investigated (Table).
- Advances in Prostanoid Therapy: New Studies, New Methods of Delivery
Two decades ago, pulmonary arterial hypertension was considered an untreatable disease. With the introduction of effective therapies this situation has changed. Today, endothelin receptor antagonists together with prostanoids and phosphodiesterase-5 (PDE5) inhibitors are the mainstays of treatment.
- Pulmonary Hypertension Roundtable
Pulmonary Hypertension Roundtable: Recapping 5 Years, Exploring Emerging Approaches
